Backend Developer (Cantonese Speaking)
Appnovation Technologies18 hours ago
Hong Kong (city not specified)Mid Level
Responsibilities
- Own the full development lifecycle of online services and Mobile Octopus solutions, including requirements analysis, system design, development, testing, deployment, and ongoing maintenance.
- Write requirements, functional, UI, interface, and data specifications and other technical documentation.
- Find and fix bugs and work with stakeholders throughout the software development lifecycle.
- Provide technical support outside office hours for urgent issues on a shift basis when needed.
Requirements
- Degree in Computer Science, Information Systems, or a related IT field.
- At least 2 years of experience developing Java web applications.
- Solid knowledge of Spring, Spring Boot, and Hibernate.
- Hands-on experience with AWS or Azure and container services such as EKS or AKS.
- Practical experience with Oracle or PostgreSQL relational databases.
- Ability to work independently and think critically.
- Strong written and spoken English and Chinese, plus good communication skills.
Benefits
- Work-life balance, professional and personal growth opportunities, and a collaborative workplace culture.
- Health benefits package, mental health support, personal days off, fertility and menopause leave, and a fitness allowance.
- Diversity, equity, and inclusion initiatives.
- The role is associated with a hybrid work arrangement and involves working at a client’s offices in Hong Kong.
Tech Stack
Categories
About Appnovation Technologies
Appnovation Technologies is a privately held digital consultancy that designs, builds, and supports customer-facing platforms for enterprises, combining strategy, UX, engineering, and managed services. Its teams deliver web and mobile development, Drupal and open-source implementations, Atlassian consulting, and data/AI-enabled solutions for large organizations. Founded in 2007 and headquartered in Vancouver, it serves global clients including Pfizer, Google, Yeti, TCL, and AstraZeneca.